EPX CRISPR/Cas9 KO Plasmid (h): sc-402513
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EPX CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the EPX genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EPX CRISPR/Cas9 KO Plasmid (h) | sc-402513 | 20 µg | $397.00 |
Overview
EPX (eosinophil peroxidase) encodes a heme-containing granule enzyme predominantly expressed in eosinophils, where it catalyzes halide- and thiocyanate-dependent oxidative reactions that contribute to antimicrobial activity and modulation of inflammatory microenvironments. By generating reactive oxidants, EPX intersects with innate immune effector pathways, redox signaling, and mechanisms of extracellular matrix remodeling that influence leukocyte recruitment and tissue injury responses. Altered EPX activity and eosinophil degranulation have been associated with eosinophilic inflammation in airway and gastrointestinal diseases, as well as hypersensitivity reactions. EPX is therefore widely used as a molecular readout for eosinophil activation and as a functional node to study oxidative stress–driven damage and immune regulation.
EPX CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the EPX gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the EPX together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the EPX open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish EPX protein expression.
This CRISPR knockout system enables efficient generation of EPX-deficient cell models for investigation of EPX signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting EPX exon(s) critical for EPX function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple EPX genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by EPX CRISPR/Cas9 KO Plasmid (h) and EPX CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the EPX locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by EPX HDR Plasmid (h) and EPX HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by EPX homology arms to support homology-directed repair at defined EPX target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.